V. Psomiadou, A. Fotiou, A. Prodromidou, C. Iavazzo
Objective: The majority of advanced ovarian cancer (OC) patients do not fully respond to systemic chemotherapy, thus complete cytoreduction can not be achieved in such cases. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been suggested as an alternative approach for these women. Our study aimed to review the literature regarding the application of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in OC patients with peritoneal carcinomatosis (PC). Data source: Articles in the English language were searched in PubMed. Search terms included “PIPAC” and “ovarian cancer”. Methods of study selection: The authors evaluated all studies presenting an application of pressurised intraperitoneal aerosol chemotherapy (PIPAC) on ovarian cancer patients. The published guidelines for Systematic Reviews and Meta-analyses (PRISMA) were followed in the present systematic review which was performed based on the authors’ predetermined inclusion criteria. Tabulation: Table 1 presents the main characteristics and outcomes of the OC patients undergoing PIPAC. Integration: Study selection and data extraction were independently undertaken by two reviewers. Results: 235 patients from 15 studies retrieved from PubMed were included. Conclusions: Our results indicate that PIPAC is efficient and safe in selected OC patients with PC not responding to systemic chemotherapy. The toxicity is manageable and the quality of life sustained. Further, randomised controlled trials are warranted to confirm our findings.
{"title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treatment of advanced ovarian cancer. A review of the literature","authors":"V. Psomiadou, A. Fotiou, A. Prodromidou, C. Iavazzo","doi":"10.31083/j.ejgo4301004","DOIUrl":"https://doi.org/10.31083/j.ejgo4301004","url":null,"abstract":"Objective: The majority of advanced ovarian cancer (OC) patients do not fully respond to systemic chemotherapy, thus complete cytoreduction can not be achieved in such cases. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been suggested as an alternative approach for these women. Our study aimed to review the literature regarding the application of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in OC patients with peritoneal carcinomatosis (PC). Data source: Articles in the English language were searched in PubMed. Search terms included “PIPAC” and “ovarian cancer”. Methods of study selection: The authors evaluated all studies presenting an application of pressurised intraperitoneal aerosol chemotherapy (PIPAC) on ovarian cancer patients. The published guidelines for Systematic Reviews and Meta-analyses (PRISMA) were followed in the present systematic review which was performed based on the authors’ predetermined inclusion criteria. Tabulation: Table 1 presents the main characteristics and outcomes of the OC patients undergoing PIPAC. Integration: Study selection and data extraction were independently undertaken by two reviewers. Results: 235 patients from 15 studies retrieved from PubMed were included. Conclusions: Our results indicate that PIPAC is efficient and safe in selected OC patients with PC not responding to systemic chemotherapy. The toxicity is manageable and the quality of life sustained. Further, randomised controlled trials are warranted to confirm our findings.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46345730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. Di Guardo, G. G. Incognito, C. Lello, Gisella D'urso, F. Genovese, M. Palumbo
Objective: This review aims to evaluate the incidence of endometrial lesions in tamoxifen-treated breast cancer patients identified by hysteroscopy (HS) and sonohysterography (SIS) and the diagnostic accuracy of the two methods to detect them. Methods: A systematic review of the literature concerning the role of HS and SIS for evaluation of the endometrium in tamoxifen-treated breast cancer patients was performed. We searched MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials, IBECS, BIOSIS, Web of Science, SCOPUS, congress abstracts, and Grey literature (Google Scholar; British Library). The search terms used were “hysteroscopy”, “hysterosonography”, “sonohysterography” combined with “tamoxifen”; 89 citations were identified and selected in the initial screening. Results: 28 studies were included in the systematic review. There were 61 citations excluded because they were review articles (n = 9) or case report (n = 5) and non-English articles (n = 8), and had too little information in the full text (n = 39). Similar accuracy between SIS and HS in detection of endometrial tamoxifen-related lesions was found. Conclusions: SIS may represent a minimally invasive, simple, safe, well-tolerated and cost-effective alternative to HS, associated with few contraindications and no potential complications.
目的:评价他莫昔芬治疗的乳腺癌患者宫腔镜(HS)和超声宫腔镜(SIS)检查子宫内膜病变的发生率及两种检查方法的诊断准确性。方法:系统回顾有关HS和SIS在他莫昔芬治疗乳腺癌患者子宫内膜评估中的作用的文献。我们检索了MEDLINE (PubMed)、EMBASE、Cochrane Central Register of Controlled Trials、IBECS、BIOSIS、Web of Science、SCOPUS、congress abstracts和Grey literature (b谷歌Scholar;英国图书馆)。使用的搜寻关键词是“宫腔镜检查”、“宫腔超声检查”、“宫腔超声检查”结合“他莫昔芬”;初步筛选筛选出89条引文。结果:系统评价纳入了28项研究。61篇引文被排除，因为它们是综述文章(n = 9)或病例报告(n = 5)和非英文文章(n = 8)，全文信息太少(n = 39)。SIS和HS在检测子宫内膜他莫昔芬相关病变方面的准确性相似。结论:SIS可能是一种微创、简单、安全、耐受性良好、成本效益高的HS替代方法，禁忌症少，无潜在并发症。
{"title":"Efficacy of sonohysterography and hysteroscopy for evaluation of endometrial lesions in tamoxifen treated patients: a systematic review","authors":"F. Di Guardo, G. G. Incognito, C. Lello, Gisella D'urso, F. Genovese, M. Palumbo","doi":"10.31083/j.ejgo4301003","DOIUrl":"https://doi.org/10.31083/j.ejgo4301003","url":null,"abstract":"Objective: This review aims to evaluate the incidence of endometrial lesions in tamoxifen-treated breast cancer patients identified by hysteroscopy (HS) and sonohysterography (SIS) and the diagnostic accuracy of the two methods to detect them. Methods: A systematic review of the literature concerning the role of HS and SIS for evaluation of the endometrium in tamoxifen-treated breast cancer patients was performed. We searched MEDLINE (PubMed), EMBASE, Cochrane Central Register of Controlled Trials, IBECS, BIOSIS, Web of Science, SCOPUS, congress abstracts, and Grey literature (Google Scholar; British Library). The search terms used were “hysteroscopy”, “hysterosonography”, “sonohysterography” combined with “tamoxifen”; 89 citations were identified and selected in the initial screening. Results: 28 studies were included in the systematic review. There were 61 citations excluded because they were review articles (n = 9) or case report (n = 5) and non-English articles (n = 8), and had too little information in the full text (n = 39). Similar accuracy between SIS and HS in detection of endometrial tamoxifen-related lesions was found. Conclusions: SIS may represent a minimally invasive, simple, safe, well-tolerated and cost-effective alternative to HS, associated with few contraindications and no potential complications.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45472687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Beirne, S. Addley, G. V. Blayney, S. McAllister, Heather J. Agnew, Elaine F Craig, I. Harley, H. Nagar, S. Dobbs, David G. Glenn, P. Comiskey, M. Stafford, W. McCluggage, S. Sinclair, M. McComiskey
Background: Endometrial cancer is the most common gynaecological malignancy in the Western world and has a strong association with obesity. The incidence of endometrial cancer is rising and can be attributed, in part, to the ongoing obesity epidemic. The surgical management of endometrial cancer in women with class III obesity, defined as those with a body mass index (BMI) ≥40 kg/m, can be particularly challenging. Case(s): We report the early experience of panniculectomy as an adjunct to endometrial cancer staging surgery in Northern Ireland (NI). We outline the generic surgical approach and report the outcomes of the first four cases undertaken. We discuss the important role that panniculectomy holds in the surgical management of endometrial cancer in women with III obesity. Conclusion: The initial experience, in NI, of panniculectomy as an adjunct to endometrial cancer staging surgery greatly facilitated surgical exposure and allowed adequate surgical staging to be performed. In carefully selected cases, the surgical procedure can be completed safely and effectively with greater ease.
{"title":"Combined panniculectomy and surgical staging of endometrial cancer: the Northern Ireland experience","authors":"J. Beirne, S. Addley, G. V. Blayney, S. McAllister, Heather J. Agnew, Elaine F Craig, I. Harley, H. Nagar, S. Dobbs, David G. Glenn, P. Comiskey, M. Stafford, W. McCluggage, S. Sinclair, M. McComiskey","doi":"10.31083/j.ejgo4301001","DOIUrl":"https://doi.org/10.31083/j.ejgo4301001","url":null,"abstract":"Background: Endometrial cancer is the most common gynaecological malignancy in the Western world and has a strong association with obesity. The incidence of endometrial cancer is rising and can be attributed, in part, to the ongoing obesity epidemic. The surgical management of endometrial cancer in women with class III obesity, defined as those with a body mass index (BMI) ≥40 kg/m, can be particularly challenging. Case(s): We report the early experience of panniculectomy as an adjunct to endometrial cancer staging surgery in Northern Ireland (NI). We outline the generic surgical approach and report the outcomes of the first four cases undertaken. We discuss the important role that panniculectomy holds in the surgical management of endometrial cancer in women with III obesity. Conclusion: The initial experience, in NI, of panniculectomy as an adjunct to endometrial cancer staging surgery greatly facilitated surgical exposure and allowed adequate surgical staging to be performed. In carefully selected cases, the surgical procedure can be completed safely and effectively with greater ease.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2022-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47151284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-29DOI: 10.21203/rs.3.rs-1079415/v1
Yanglong Guo, Xi Chen, Q. Lin, T. Zhu, Yingli Zhang
Background: This study investigated the clinicopathological characteristics and factors influencing the recurrence of pelvic endodermal sinus tumor. Methods: Fifty-four cases were retrospectively analyzed from at the Zhejiang Cancer Hospital. Imaging and serological indicators were used to determine whether disease recurred, to evaluate progression-free survival, and to compare the influence of related factors on disease recurrence. SPSS 19.0 software was used for statistical analysis. Statistical significance was defined as p < 0.05. Results: The median age at initial treatment was 21 years (range, 11–52 years). Six patients had extragonadal endodermal sinus tumor, and four had histological features of endodermal sinus tumor combined with embryonal carcinoma. Thirty-nine patients underwent fertility-preserving surgery, 18 patients had a childbearing history, and eight patients had residual tumor after initial treatment. Twenty-six patients had a tumor diameter of more than 15 cm, and 30 patients had a serum α‑fetoprotein level greater than 10,000 ng/mL before initial management. The median follow-up time was 47.5 months (range, 14–212 months). During follow-up, 15 patients experience recurrence, with a recurrence rate of 27.8% and a 5-year PFS rate of 61.1%. In univariate analysis, the International Federation of Gynecology and Obstetrics stage (stage III-IV VS. I-II; HR= 10.054 p<0.001), residual tumor (yes VS. no for the first surgery; HR=5.014 p=0.001), histological features (endodermal sinus tumor combined with embryonal carcinoma VS. endodermal sinus tumor; HR=4.130 p=0.018), and use of platinum-based chemotherapy (courses≥3 VS. courses<3; HR= 0.188 p=0.004) were independent factors influencing recurrence; age, childbearing history, tumor site, tumor size, and serum α-fetoprotein level before initial management did not affect recurrence. In multivariate analysis, only stage was an independent risk factor for progression-free survival（stage III-IV VS. I-II; HR=6.923 p=0.019）. Conclusions: Stage is a prognostic factor for recurrence of pelvic endodermal sinus tumor. The first surgery should remove the tumor as completely as possible, and initial treatment should require a sufficient dose and full course of platinum-based chemotherapy, which may reduce the recurrence rate. Patients with endodermal sinus tumor and embryonal carcinoma may have increased susceptibility of recurrence.
{"title":"Clinical Characteristics and Risk Factors Analysis for the Recurrence of Pelvic Endodermal Sinus Tumors","authors":"Yanglong Guo, Xi Chen, Q. Lin, T. Zhu, Yingli Zhang","doi":"10.21203/rs.3.rs-1079415/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-1079415/v1","url":null,"abstract":"\u0000 Background: This study investigated the clinicopathological characteristics and factors influencing the recurrence of pelvic endodermal sinus tumor. Methods: Fifty-four cases were retrospectively analyzed from at the Zhejiang Cancer Hospital. Imaging and serological indicators were used to determine whether disease recurred, to evaluate progression-free survival, and to compare the influence of related factors on disease recurrence. SPSS 19.0 software was used for statistical analysis. Statistical significance was defined as p < 0.05. Results: The median age at initial treatment was 21 years (range, 11–52 years). Six patients had extragonadal endodermal sinus tumor, and four had histological features of endodermal sinus tumor combined with embryonal carcinoma. Thirty-nine patients underwent fertility-preserving surgery, 18 patients had a childbearing history, and eight patients had residual tumor after initial treatment. Twenty-six patients had a tumor diameter of more than 15 cm, and 30 patients had a serum α‑fetoprotein level greater than 10,000 ng/mL before initial management. The median follow-up time was 47.5 months (range, 14–212 months). During follow-up, 15 patients experience recurrence, with a recurrence rate of 27.8% and a 5-year PFS rate of 61.1%. In univariate analysis, the International Federation of Gynecology and Obstetrics stage (stage III-IV VS. I-II; HR= 10.054 p<0.001), residual tumor (yes VS. no for the first surgery; HR=5.014 p=0.001), histological features (endodermal sinus tumor combined with embryonal carcinoma VS. endodermal sinus tumor; HR=4.130 p=0.018), and use of platinum-based chemotherapy (courses≥3 VS. courses<3; HR= 0.188 p=0.004) were independent factors influencing recurrence; age, childbearing history, tumor site, tumor size, and serum α-fetoprotein level before initial management did not affect recurrence. In multivariate analysis, only stage was an independent risk factor for progression-free survival（stage III-IV VS. I-II; HR=6.923 p=0.019）. Conclusions: Stage is a prognostic factor for recurrence of pelvic endodermal sinus tumor. The first surgery should remove the tumor as completely as possible, and initial treatment should require a sufficient dose and full course of platinum-based chemotherapy, which may reduce the recurrence rate. Patients with endodermal sinus tumor and embryonal carcinoma may have increased susceptibility of recurrence.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"1 1","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41549283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-11-11DOI: 10.21203/rs.3.rs-655431/v1
F. Meng, Yunyun Cao, Yudong Wang
Objective: The aim of this study was to explore the clinical characteristics of patients with VaIN and identify more sensitive diagnostic methods.Methods: This study retrospectively analyzed 657 patients with VaIN from the International Peace Maternal and Child Health Hospital in Shanghai during a ten-year period. Results: Among the 657 patients, 26.5% were diagnosed with VaIN 2/3. The proportions of patients with VaIN 2/3 among those who did and did not undergo hysterectomy were 39.5% and 24.7%, respectively. The sensitivity of cytology for VaIN in those with only VaIN, VaIN concomitant with cervical or vulvar lesions, and posthysterectomy VaIN was 56.7%, 66.5%, and 72.3%, respectively. The sensitivity of hrHPV for VaIN in the same categories was 87.7%, 86.5%, and 74.3%, respectively. The sensitivity of cytology and hrHPV cotesting for VaIN in the same categories was 95.2%, 95.6%, and 95.0%, respectively. In patients who did not undergo hysterectomy, HPV16 was detected in 9.5% of VaIN 1 lesions among the HPV DNA-positive patients, while the other 12 types of HPV were detected in 62.6% of VaIN 1 lesions. In patients who underwent hysterectomy, HPV16 was detected in 2.1% of VaIN 1 lesions, and the other 12 types of HPV were detected in 54.2% of VaIN 1 lesions.Conclusions: A combination of cytology and colposcopy could increase the sensitivity of the diagnosis of VaIN. The other 12 high-risk types of HPV positive may be more closely related to VAIN 1, more attention should be paid.
{"title":"A Retrospective Study of 657 Women With Vaginal Intraepithelial Neoplasia (VaIN)","authors":"F. Meng, Yunyun Cao, Yudong Wang","doi":"10.21203/rs.3.rs-655431/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-655431/v1","url":null,"abstract":"\u0000 Objective: The aim of this study was to explore the clinical characteristics of patients with VaIN and identify more sensitive diagnostic methods.Methods: This study retrospectively analyzed 657 patients with VaIN from the International Peace Maternal and Child Health Hospital in Shanghai during a ten-year period. Results: Among the 657 patients, 26.5% were diagnosed with VaIN 2/3. The proportions of patients with VaIN 2/3 among those who did and did not undergo hysterectomy were 39.5% and 24.7%, respectively. The sensitivity of cytology for VaIN in those with only VaIN, VaIN concomitant with cervical or vulvar lesions, and posthysterectomy VaIN was 56.7%, 66.5%, and 72.3%, respectively. The sensitivity of hrHPV for VaIN in the same categories was 87.7%, 86.5%, and 74.3%, respectively. The sensitivity of cytology and hrHPV cotesting for VaIN in the same categories was 95.2%, 95.6%, and 95.0%, respectively. In patients who did not undergo hysterectomy, HPV16 was detected in 9.5% of VaIN 1 lesions among the HPV DNA-positive patients, while the other 12 types of HPV were detected in 62.6% of VaIN 1 lesions. In patients who underwent hysterectomy, HPV16 was detected in 2.1% of VaIN 1 lesions, and the other 12 types of HPV were detected in 54.2% of VaIN 1 lesions.Conclusions: A combination of cytology and colposcopy could increase the sensitivity of the diagnosis of VaIN. The other 12 high-risk types of HPV positive may be more closely related to VAIN 1, more attention should be paid.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48650864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Englert-Golon Monika, Słopień Radosław, S. Natalia, Burchardt Bartosz, S. Stefan
Department of Operative Gynecology, University of Medical Sciences of Poznań, 61-841 Poznań, Poland Department of Gynecological Endocrinology, University of Medical Sciences of Poznań, 61-841 Poznań, Poland Department of Mother’s and Child’s Health, University of Medical Sciences of Poznań, 61-841 Poznań, Poland Forensic Medicine Department, University of Medical Sciences of Poznań, 61-841 Poznań, Poland
{"title":"Synchronous ovarian, endometrial and cervical cancer—case report","authors":"Englert-Golon Monika, Słopień Radosław, S. Natalia, Burchardt Bartosz, S. Stefan","doi":"10.31083/j.ejgo4205158","DOIUrl":"https://doi.org/10.31083/j.ejgo4205158","url":null,"abstract":"Department of Operative Gynecology, University of Medical Sciences of Poznań, 61-841 Poznań, Poland Department of Gynecological Endocrinology, University of Medical Sciences of Poznań, 61-841 Poznań, Poland Department of Mother’s and Child’s Health, University of Medical Sciences of Poznań, 61-841 Poznań, Poland Forensic Medicine Department, University of Medical Sciences of Poznań, 61-841 Poznań, Poland","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43005216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L. Mainar, J. Sierra, Leticia Alvarez Sarrado, Y. Gutiérrez, M. Ballestero, Patricia Rubio Cuesta, A. C. Peña, Andrea Espiau Romera
Objective: To compare pre-surgical demographic and clinical factors and preoperative serum tumor marker values of patients with endometrial and ovarian synchronous carcinoma with those diagnosed with endometrial carcinoma with metastatic ovarian involvement (FIGO stage IIIA). Methods: A retrospective observational study including patients with endometrial and ovarian malignant tumors that were treated at Miguel Servet University Hospital, Zaragoza, Spain, since January 2000 to June 2020. All pathologic specimens were reviewed by two pathologists specialized in gynecological oncology. Results: Overall, 51 patients were included. 24 cases of them, were endometrial and ovarian synchronous primary carcinomas and the remaining 27 cases were endometrial tumors with adnexa. Parity, personal and family oncological history, arterial hypertension, diabetes, dyslipidemia, obesity and the prior use of hormone replacement therapy did not show significant differences between both groups. Age (p = 0.002), menopausal status (p = 0.029), abnormal uterine bleeding (p = 0.001), Ca 12.5 preoperative serum level (p = 0.038) and Ca 19.9 preoperative serum level (0.028) were factors with significant differences between both groups. In multivariate analysis, only abnormal uterine bleeding and Ca 19.9 values were independents factors. Conclusions: The presence of abnormal uterine bleeding and Ca 19.9 preoperative serum level could guide the clinician in the preoperative differential diagnosis between endometrial cancer with ovarian involvement and endometrial and ovarian synchronous carcinoma.
{"title":"Clinical and demographic factors in endometrial and ovary carcinoma: synchronous carcinoma vs stage IIIA endometrial carcinoma","authors":"L. Mainar, J. Sierra, Leticia Alvarez Sarrado, Y. Gutiérrez, M. Ballestero, Patricia Rubio Cuesta, A. C. Peña, Andrea Espiau Romera","doi":"10.31083/j.ejgo4204099","DOIUrl":"https://doi.org/10.31083/j.ejgo4204099","url":null,"abstract":"Objective: To compare pre-surgical demographic and clinical factors and preoperative serum tumor marker values of patients with endometrial and ovarian synchronous carcinoma with those diagnosed with endometrial carcinoma with metastatic ovarian involvement (FIGO stage IIIA). Methods: A retrospective observational study including patients with endometrial and ovarian malignant tumors that were treated at Miguel Servet University Hospital, Zaragoza, Spain, since January 2000 to June 2020. All pathologic specimens were reviewed by two pathologists specialized in gynecological oncology. Results: Overall, 51 patients were included. 24 cases of them, were endometrial and ovarian synchronous primary carcinomas and the remaining 27 cases were endometrial tumors with adnexa. Parity, personal and family oncological history, arterial hypertension, diabetes, dyslipidemia, obesity and the prior use of hormone replacement therapy did not show significant differences between both groups. Age (p = 0.002), menopausal status (p = 0.029), abnormal uterine bleeding (p = 0.001), Ca 12.5 preoperative serum level (p = 0.038) and Ca 19.9 preoperative serum level (0.028) were factors with significant differences between both groups. In multivariate analysis, only abnormal uterine bleeding and Ca 19.9 values were independents factors. Conclusions: The presence of abnormal uterine bleeding and Ca 19.9 preoperative serum level could guide the clinician in the preoperative differential diagnosis between endometrial cancer with ovarian involvement and endometrial and ovarian synchronous carcinoma.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43725385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Shah, Gabriela M. Oprea, S. Shafi, P. Surapaneni, Sanjay R. Jain
{"title":"Prognostic significance of hormone receptor (ER/PR) status in endometrial carcinoma in black women: implications with lymph node metastasis","authors":"M. Shah, Gabriela M. Oprea, S. Shafi, P. Surapaneni, Sanjay R. Jain","doi":"10.31083/j.ejgo4204121","DOIUrl":"https://doi.org/10.31083/j.ejgo4204121","url":null,"abstract":"","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48721021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Plagens-Rotman, P. Merks, G. Jarząbek-Bielecka, M. Mizgier
Hipolit Cegielski State University of Applied Sciences, Institute of Health Sciences, 62-200 Gniezno, Poland Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, A. Jurasza 2, 85-089 Bydgoszcz, Poland Faculty of Medicine, Collegium Medicum. Cardinal Stefan Wyszyński University in Warsaw, 01-938 Warsaw, Poland Division of Developmental Gynecology and Sexology, Department of Perinatology and Gynecology, Poznan University of Medical Sciences, 60-535 Poznań,
{"title":"Does the consumption of pasta, rice and groats affect the risk of cancer of women’s reproductive organs and breast?","authors":"K. Plagens-Rotman, P. Merks, G. Jarząbek-Bielecka, M. Mizgier","doi":"10.31083/j.ejgo4204101","DOIUrl":"https://doi.org/10.31083/j.ejgo4204101","url":null,"abstract":"Hipolit Cegielski State University of Applied Sciences, Institute of Health Sciences, 62-200 Gniezno, Poland Department of Pharmaceutical Technology, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, A. Jurasza 2, 85-089 Bydgoszcz, Poland Faculty of Medicine, Collegium Medicum. Cardinal Stefan Wyszyński University in Warsaw, 01-938 Warsaw, Poland Division of Developmental Gynecology and Sexology, Department of Perinatology and Gynecology, Poznan University of Medical Sciences, 60-535 Poznań,","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42449949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Ahmed-Salim, S. Saso, Hannah E Meehan, N. Galazis, D. L. Phelps, B. Jones, M. Chan, Mehar Chawla, K. Lathouras, H. Gabra, C. Fotopoulou, S. Ghaem-Maghami, J. Smith
Department of Obstetrics and Gynaecology, The Hillingdon Hospitals NHS Foundation Trust, UB8 3NN London, UK Department of Gynaecological Oncology, Institute of Reproductive & Developmental Biology, Imperial College London, W12 0HS London, UK Department of Obstetrics and Gynaecology, Imperial College NHS Healthcare Trust, W12 0HS London, UK Department of Obstetrics and Gynaecology, St Mary’s Hospital, W2 1NY London, UK Department of Gynaecological Oncology, Imperial College NHS Trust, W12 0HS London, UK Division of Surgery and Cancer, Imperial College London, W12 0HS London, UK Department of Obstetrics and Gynaecology, North Middlesex NHS Trust, N18 1QX London, UK West London Gynaecological Cancer Centre, Queen Charlotte’s Hospital, Imperial College London, W12 0HS London, UK Department of Medical Oncology, Imperial College London, W12 0HS London, UK West London Gynaecological Cancer Centre, Queen Charlotte’s Hospital, Imperial College London, W12 0HS London, UK
{"title":"A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer","authors":"Y. Ahmed-Salim, S. Saso, Hannah E Meehan, N. Galazis, D. L. Phelps, B. Jones, M. Chan, Mehar Chawla, K. Lathouras, H. Gabra, C. Fotopoulou, S. Ghaem-Maghami, J. Smith","doi":"10.31083/j.ejgo4204102","DOIUrl":"https://doi.org/10.31083/j.ejgo4204102","url":null,"abstract":"Department of Obstetrics and Gynaecology, The Hillingdon Hospitals NHS Foundation Trust, UB8 3NN London, UK Department of Gynaecological Oncology, Institute of Reproductive & Developmental Biology, Imperial College London, W12 0HS London, UK Department of Obstetrics and Gynaecology, Imperial College NHS Healthcare Trust, W12 0HS London, UK Department of Obstetrics and Gynaecology, St Mary’s Hospital, W2 1NY London, UK Department of Gynaecological Oncology, Imperial College NHS Trust, W12 0HS London, UK Division of Surgery and Cancer, Imperial College London, W12 0HS London, UK Department of Obstetrics and Gynaecology, North Middlesex NHS Trust, N18 1QX London, UK West London Gynaecological Cancer Centre, Queen Charlotte’s Hospital, Imperial College London, W12 0HS London, UK Department of Medical Oncology, Imperial College London, W12 0HS London, UK West London Gynaecological Cancer Centre, Queen Charlotte’s Hospital, Imperial College London, W12 0HS London, UK","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":" ","pages":""},"PeriodicalIF":0.4,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41604530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：